Prior authorization criteria for anifrolumab (Saphnelo) for systemic lupus erythematosus
Customize your policy alerts
Sign up for allcareadvantage Policy 125.1 alerts
Get alerted when Policy 125.1 changes without checking for updates manually.
Monitor payer policy activity
Prior authorization criteria for coverage of anifrolumab (Saphnelo) for adults with moderate to severe systemic lupus erythematosus when used with standard therapy; applies to AllCare Advantage / AllCare CCO members.
No material clinical or coverage changes in this revision.
Coverage Criteria for Anifrolumab (Saphnelo)
inv-01: Initial therapy — Covered when ALL of the following are met
Covered when ALL of the following are met:
If all criteria are met, approve for 6 months.
inv-02: Continuation / renewal — Renewal criteria to continue beyond initial approval
Renewal criteria (to continue beyond initial approval):
If renewal requirements are met, approval is continued; failure to meet requirements results in denial of renewal.
Anifrolumab is not approved for patients with severe active central nervous system (CNS) lupus. Presence of severe active CNS lupus is an exclusion and will result in denial of coverage under this policy.
Use of anifrolumab in patients under 18 years of age is not FDA‑approved and will be denied. Requests will also be denied when the medical record lacks objective documentation of moderate to severe SLE or when there is no documentation that the patient failed to respond adequately to at least one standard therapy prior to initiating anifrolumab.
Coding and Age Indication
| anifrolumab | Saphnelo (type 1 interferon receptor inhibitor) - drug included in criteria |
Provider Actions, Requirements, and Denial Triggers
Prior authorization required; approval only when all criteria met
Prior authorization is required for anifrolumab (Saphnelo) and will be approved only when all specified clinical criteria are met, including adult age, specialty involvement, objective disease documentation, prior inadequate response to standard therapy, use with standard therapy, absence of exclusions, and not being used with other biologics. If all criteria are met, approve for 6 months.
Step therapy — trial of ≥1 standard therapy required
Patient must have failed to respond adequately to at least one standard therapy (concomitant background SLE therapies such as immunosuppressants, antimalarials, or corticosteroids) before anifrolumab will be approved.
- Failure to respond to at least one standard therapy is a denial trigger if not met.
Required clinical documentation (disease activity and baseline assessment)
Submit objective documentation of active autoantibody‑positive SLE, a baseline assessment of SLE disease activity using a validated assessment tool, and objective documentation that disease is moderate to severe.
- Baseline validated SLE disease activity assessment is required; lack of this assessment may result in denial.
- Documentation must show active autoantibody‑positive SLE and objective evidence of moderate to severe disease.
Denial triggers — prescriber specialty, age, missing assessments, exclusions
Denials will be issued if the prescription is not written by or in consultation with a rheumatologist or nephrologist, if the patient is under 18 years of age, or when other listed exclusion/criteria failures are present.
- Prescription not written by (or in consultation with) a rheumatologist or nephrologist → Deny.
- Patient age ≤18 years (not FDA approved for pediatric patients) → Deny.
- Lack of baseline validated disease activity assessment or inadequate objective documentation of moderate to severe disease → Deny.
- Requested agent not used in combination with standard therapy, requested agent used with other biologics, or presence of exclusion (e.g., severe active CNS lupus) → Deny.
- Failure to try at least one standard therapy → Deny.
Definitions and Standard Therapy
Background
Anifrolumab (Saphnelo) is a type 1 interferon receptor inhibitor approved for the treatment of moderate to severe systemic lupus erythematosus (SLE) in adults, to be used in combination with standard SLE therapy. The policy requires that prescriptions be written by or in consultation with a rheumatologist or nephrologist, that patients have active autoantibody‑positive SLE with a baseline assessment using a validated disease activity tool, and that objective documentation demonstrates moderate to severe disease. When all criteria are met and no exclusions apply, coverage is approved for 6 months, with renewal contingent on specialty follow‑up and documented clinical improvement.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.